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The effects of tobacco use on
oral health
Objective. To review the effects of tobacco use on oral health, with particular
emphasis on the effects of periodontal diseases, dental implant failures, and risk
of development of oral cancers and precancers.
Data sources. Medline literature search (1977-2002).
Study selection. Key words for the literature search were ‘tobacco smoking’,
‘periodontal disease’, ‘dental implant’, and ‘oral cancers and precancers’.
Data extraction. Evidence-based literature review.
Data synthesis. The prevalence and severity of periodontal diseases in their
various forms are higher among smokers than among non-smokers. The success
of dental implant treatments is significantly influenced by addiction to tobacco
smoking. The failure rate of implant osseointegration is considerably higher
among smokers, and maintenance of oral hygiene around the implants and the
risk of peri-implantitis are adversely affected by smoking. The risks of developing
oral cancers and precancers are greater in smokers. Betel nut chewing and
smokeless tobacco produce similar risk to cancer incidence as tobacco smoking.
Cessation of tobacco use has a beneficial effect on halting the progression of
periodontal diseases and on the outcome of periodontal therapy.
Conclusions. Medical and dental teams should be aware of oral problems
associated with tobacco use. Counselling on smoking cessation and smoking
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Introduction
Tobacco smoking is linked with many serious illnesses, such as cancer, cardio-
pulmonary diseases, low birthweight, as well as with many health problems.1 It
is also linked to a detrimental impact on oral health, such as increasing risk of
periodontal (gum) diseases. In addition, dental implant failure is more common
among smokers than among non-smokers, and peri-implantitis among smokers
is also more prevalent.2 Tobacco can be consumed through the mouth in a variety
of forms, varied from smoking to smokeless tobacco chewing on itself or combined
with betel nut. These may induce a variety of oral manifestations of diseases
(Box 1). These lesions most likely result from the many irritants, toxins, and
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carcinogens found in the smoke emitted from burning
tobacco, but they may also arise from drying of the mucosa
by the high intra-oral temperature, pH change, alteration in
immune response, or altered resistance to fungal or viral
infections. Other effects include halitosis, staining of teeth
and composite restorations,3 decreased ability to taste and
smell, and nicotinic stomatitis and keratosis.4 Most of these
problems are reversible after cessation of tobacco use.5
The aim of this article is to present an evidence-based
comprehensive literature review for medical and dental
practitioners on the effect of tobacco smoking on oral health,
particularly on the risk of periodontal diseases, dental
implants, and oral cancers.
Tobacco smoking and periodontal diseases
Periodontal diseases, including gingivitis and periodontitis,
are common human bacterial infections that affect the
gingiva and bone supporting the teeth. Gingivitis is a form
of inflammation limited to the marginal gingival tissues, and
is usually caused by the accumulation of dentogingival
plaque due to inadequate oral hygiene. Gingivitis is
reversible with professional treatment and good oral care at
home. Untreated gingivitis may advance to periodontitis
under certain conditions when plaque accumulates below
the gingival line. Periodontitis refers to the destructive
inflammation that results in irreversible loss of periodontal
attachment and tooth-supporting alveolar bone. Ap-
proximately 17% of the adult population in Hong Kong has
severe chronic periodontitis.6 Gingival recession may result
from periodontal destruction and exposure of part of the
root surfaces of teeth to the oral environment. The exposed
root surfaces are at risk of developing root surface caries.
Furthermore, root surface caries among individuals with
gingival recession is more prevalent among tobacco smokers
than among non-smokers.7
Effects of smoking on the prevalence and severity of
periodontal diseases
Epidemiological studies have demonstrated that tobacco use
is a significant risk factor for the development of periodontal
diseases.8,9 Disease severity increases with the frequency of
smoking.9,10 Smokers accumulate markedly more dental
calculus than do non-smokers, and the quantity of calculus
is correlated with the frequency of smoking.11,12 Smoking is
also associated with an increased risk of periodontal
attachment loss and formation of periodontal pockets, as
well as alveolar bone loss (Fig 1). The adverse effects of
smoking on the periodontium correlates well with both the
quantity of daily consumption and the duration.13,14 Ap-
proximately half of the cases of periodontitis in the United
States have been attributed to smoking.15 Smokers were
recorded to have a 2.5 to 3.5 times greater risk of severe
periodontal attachment loss.8 In analyses that adjusted for
different oral hygiene habits, patient age, sex, and socio-
economic level, smokers had deeper periodontal pockets,
increased alveolar bone loss, increased tooth mobility, and
more tooth loss than did non-smokers.16 In addition,
emotional stress and poor oral hygiene seem to play an
important interactive role with tobacco smoking.17
Acute necrotising gingivitis is also strongly correlated
with tobacco use.18 Although the precise cause of this disease
remains unknown, it tends to occur most frequently in
teenagers and young adults. Some patients with acute
necrotising gingivitis have defective neutrophil function,
thereby allowing bacterial, or possibly viral (cytomegalo-
virus) invasion of gingival tissues.19 The gingival bleeding
in smokers is ‘less severe’ than in non-smokers, which could
be related to the vasoconstrictive effect of the nicotine.20
The main vasoconstrictive property of nicotine exerts its



























Box 1. Oral lesions and conditions associated with tobacco
use
Fig 1. A heavy smoking subject with generalised chronic
periodontitis
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other tobacco components can also induce tissue necrosis
and ulceration seen in the disease. Smokeless tobacco users
have an incidence of gingivitis and gingival bleeding that is
similar to the incidence among non-users. Nevertheless,
use of this form of tobacco is known to produce a painless
loss of gingival tissues and alveolar bone destruction in the
area of chronic tobacco contact, as a result of collagen
breakdown due to increased release of collagenase.21
Nicotine inhibits the growth of gingival fibroblasts and their
production of fibronectin and collagen.21 Furthermore, oral
leukocytes, especially neutrophils, may exhibit diminished
ability to migrate and phagocytose, and they contribute to
the inactivation of tissue proteinase inhibitors.22 Tobacco
smoking may exert a masking effect on gingival symptoms
of inflammation, which might give smoking patients a false
sense of assurance of gingival health.23 Smoking upregulates
the expression of pro-inflammatory cytokines, such as
interleukin-1, which contributes to increased tissue damage
and alveolar bone resorption.22 Interleukin-1 genotype-
positive smokers are more susceptible to severe adult
periodontitis.24 The effect of tobacco smoking on periodontal
tissues is summarised in Fig 2.
Effects of smoking on periodontal therapy outcomes
Smokers respond less favourably than non-smokers to non-
surgical25,26 and surgical periodontal therapy.27 Smokers
exhibited less improvement when compared with non-
smokers, in terms of pocket depth reduction, resolution of
gingival inflammation, and clinical attachment level.25,26,28
Heavy smokers (ie smoking >10 cigarettes per day) exhibited
a lower degree of probing-depth reduction and less gain in
clinical attachment level than did ex-smokers and non-
smokers during active periodontal treatment.29,30 In addition,
current smokers have poor healing ability, which may be
associated with persistent subgingival infection with
Bacteroides forsythus and Porphyromonas gingivalis
following subgingival scaling and root planning when
compared with ex-smokers and non-smokers.31 Cigarette
smoking adversely affects outcomes of guided-tissue
regeneration treatment (which aims to encourage
regeneration of lost periodontal attachment) in terms of
reduction in recession, gain of clinical attachment and
probing-bone, and root coverage.32,33 However, up to 90%
of refractory periodontitis patients are smokers.34 Because
smokers have different treatment response patterns
Fig 2. Effects of tobacco smoking on periodontal tissues
* PMN polymorphonuclear leukocytes
† IgA, IgG immunoglobulin A, immunoglobulin G
‡ IL-1 interleukin-1
§ TNF-α tumour necrosis factor–alpha
|| PGE2 prostaglandin E2
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and healing dynamics, a short-term study conducted by
Jin et al35 suggested that smoking patients need a more
intensive treatment regimen to achieve a better treatment
outcome.
Periodontal effects of smoking cessation
Smoking cessation is beneficial to periodontal treatment
outcomes and periodontal health. An encouraging finding
is that periodontal disease progression also slows down in
individuals who quit smoking. Smoking cessation may even
restore the normal periodontal and microbial healing
responses: the healing response of ex-smokers can even
become similar to that of non-smokers.30,31
Smokers who have been treated for periodontal diseases
should be recalled more frequently for professional
examination, reinforcement of oral hygiene instruction,
intensive scaling, and prophylaxis after completion of
treatment. Smoking is known to influence the com-
position of the subgingival microflora in adult patients
with periodontitis, and the habit may predispose to the
development of a specific population of periodontal
pathogens.36 Therefore, a combination of antibiotic
therapy and participation in a smoking cessation pro-
gramme may be the most effective treatment of smoking-
induced periodontal diseases.37,38
Dental implant failure
Tobacco smoking contributes to increased tooth mobility39
and tooth loss occurs 1.53 times more frequently in smokers
than in non-smokers.40,41 Tooth loss reduces the oral chewing
function and quality of life and leads to the subsequent
demand for tooth replacement, such as dentures or implant-
supported prostheses.
Furthermore, smoking addiction is directly related to
dental implant failure,42,43 and there is a general consensus
on the negative effect of smoking on implant survival.44
Significantly greater proportions of implant failures occur
in smokers than in non-smokers (11.28% versus 4.76%).43
Furthermore, Wallace45 showed a failure rate of 16.6% in
smokers, compared with 6.9% in non-smokers after a review
of 56 patients having 187 endosseous dental implants over
a 4-year period; shorter implants (<10 mm in length) were
more susceptible to failure in smokers.45 In this study, the
failure rate before loading the implants was 9% in smokers
versus 1% in non-smokers, which was statistically sig-
nificant, even though the bone quality in both groups was
comparable.
Peri-implantitis is the formation of deep mucosal pockets
around dental implants, inflammation of the peri-implant
tissues, and increased resorption of implant-surrounding
bone. Chronic peri-implantitis results in implant failure when
left untreated.2 Tobacco use may directly compromise the
osseointegration of root-form dental implants.45 The
difference in peri-implant bone loss is significant in the
mandible between smokers and non-smokers but insig-
nificant in the maxilla.46,47 The combination of smoking and
plaque-induced inflammation significantly influences bone
loss around the implants,46 whereas occlusal loading has only
a minor role.
Smoking cessation protocols show considerable promise
in improving the success rate of osseointegration in smokers
who overcome the addiction, with significant differences
between failure rates between non-smokers and smokers and
between smokers who adopted the smoking cessation
protocol and those who continue smoking.48
Oral precancerous lesions
Leukoplakia and erythroplakia
A clinical definition of leukoplakia was formulated by the
World Health Organization in 1978. Oral leukoplakia is cur-
rently defined as a predominantly white lesion of the oral
mucosa that cannot be characterised as any other de-
finable lesion; some of these lesions will develop into can-
cer (Fig 3).49 The recent classification and staging system
also incorporates provisional and definitive diagnoses on
the basis of histopathological features of persistent lesions
lasting longer than 2 to 4 weeks, such as the size of the
leukoplakia and the presence of epithelial dysplasia. A
diagnosis of oral leukoplakia results from the recognition
of several levels of certainty (C), an approach that is
analogous to the use of the C-factor in the tumour-node-
metastatis classification system.49 Smokers with oral
premalignant lesions such as leukoplakia and erythro-
plakia (red patches or plaques that cannot be characterised
clinically or pathologically as any other conditions) have
an annual cancer transformation rate of about 5% (Fig 4).50
A case-control study, conducted by Shiu et al51 in Taiwan,
showed that the adjusted ratio for betel nut chewing and
smoking on the occurrence of leukoplakia were 17.43 and
3.22, respectively. These findings suggested that stopping
smoking may reduce the number of leukoplakia cases by
36%, while elimination of betel nut influence may prevent
62% cases of leukoplakia and 26% of cases of malignant
transformation to oral carcinoma.
Smokeless tobacco keratosis
Snuff pouch or smokeless tobacco keratosis is a white
keratotic lesion. It has a translucent appearance rather than
an opaque whiteness. The microscopic appearance of tissue
from a lesion does not reveal excessive keratinisation, which
is characteristic of leukoplakia. This lesion is located only
in areas of direct contact with snuff or chewed tobacco and
is reversible when the affected patients stop the habit.
Many oral cancers, on the other hand, do not go through
a premalignant stage, and not all premalignant lesions will
become malignant; some may even regress with time.52 The
degree of histological epithelial dysplasia and the clinical
characteristics are the most reliable markers in predicting
malignant potential.
Hong Kong Med J Vol 9 No 4 August 2003      275
Effects of tobacco on oral health
Oral cancer
Oral cancer is dominated by squamous cell carcinoma
(present in 90%-95% of all oral cancers), and the role of
tobacco in the development of oral squamous cell carcinoma
is well recognised (Fig 5). The long-term prognosis is quite
poor, and treatment can lead to further functional and
cosmetic problems. Tobacco use, including reverse smoking
(smoking with the lit end inside the mouth), chewing of betel
quid (a mixture of areca nut, slaked lime, and tobacco
wrapped in betel leaf), and use of smokeless tobacco
(smokeless tobacco products are not licensed for sale in
Hong Kong52), increases the risk of cancers of the upper
aerodigestive tract. Oral cancer is also associated with
alcohol consumption.53,54 Alcohol is capable of making the
mucosa more susceptible to malignant transformation by
the tobacco carcinogens, such as polycyclic aromatic
hydrocarbons, formaldehyde, and nitrosamines. Tobacco
smoking and betel nut chewing with or without smokeless
tobacco use may induce mutations in p53 and Rb tumour
suppressor genes.55,56 Glutathione S-transferase M1
(GSTM1) and T1 (GSTT1) enzymes are both involved in
the metabolism of environmental carcinogens, including
tobacco-derived carcinogens. The prevalence of null
genotypes of GSTM1 and GSTT1 is high among cases of
oral cancer,57 with both null genotypes occurring together
in 60.2% of cases in one study.58
Carcinogenesis of squamous cell carcinoma in the lung
and oral cavity due to carcinogens present in tobacco and
tobacco smoke may be correlated. Genetic polymorphisms
of glutathione synthesis and glutathione-dependent enzymes
have been studied with respect to the susceptibility to lung
cancer.59 Genetic combinations, such as mutations in the
gene encoding cytochrome P450 (CYP) 1A1 and the
GSTM1-null genotype, may predispose the lung and oral
cavity of smokers to an even higher risk of carcinogenesis
or DNA damage.60 Major classes of carcinogens present in
tobacco and tobacco smoke can be converted into DNA-
reactive metabolites by CYP-related enzymes, but a study
conducted in Japan showed that the GSTM1-null genotype
had only a weak correlation with oral cancers and genetic
polymorphism of GSTT1, CYP1A1, and CYP2E1 genes were
not associated with such cancers.61 Retinoids or beta-
carotene, isothiocyanates and tea polyphenols have also been
identified as possible chemo-preventive agents for cancers
of the lung and oral cavity, but study results remain
controversial.60 More molecular epidemiological evidence
is required to confirm the gene-to-gene and gene-to-
environment interactions in the development of oral cancers
influenced by the different forms of tobacco smoking,
especially among different ethnicities and races.
Smoking cessation strategies
Smoking is a chronic condition that requires long-term
management. Dental treatment outcomes may be
unpredictable for patients who continue to smoke. The
financial burden may be increased when a more intensive
treatment plan is required to achieve oral health. The most
substantial decreases in management costs may be achieved
for patients who stop smoking at an early stage.
Smoking cessation efforts are divided into two broad
categories: pharmacological and behavioural. Pharma-
Fig 3. Homogenous leukoplakia on the left alveolar gingiva of
the mandible
Fig 4. Tongue lesion with (A) epithelial dysplasia at the
whitish area and (B) carcinoma at the ulcerative area
Fig 5. Invasive squamous cell carcinoma on the posterior
mandible in a 66-year-old smoker
Sham et al
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cological approaches currently include two general
strategies: nicotine replacement and bupropion therapy. In
April 2002, the National Institute for Clinical Excellence in
the United Kingdom released guidelines to health care
professionals on the use of nicotine replacement therapy
(NRT) and non-NRT, such as bupropion (Zyban; Glaxo
Welcome, London, UK) for smoking cessation.62 Nicotine
replacement therapy reduces physical withdrawal symptoms.
Nicotine gum, transdermal patch, nasal spray, inhalers,
sublingual tablets, and lozenges are examples of NRT
products available.63 Chewing nicotine gums and applying
skin patches allow nicotine to be absorbed through the
mucosa of the oral cavity and skin, respectively, thereby
reducing the craving for nicotine and allowing patients to
focus on changing their behaviour. Bupropion is the first
prescribed non-nicotine pharmacological agent shown to be
effective for smoking cessation, and it has been approved
by the United States Food and Drug Administration for
that use.64 Bupropion is an antidepressant that acts on
dopaminergic pathways in the central nervous system.65
The combination of bupropion with NRT via a trans-
dermal system has the highest success rates of cessation
treatments.65 Success of smoking cessation using
pharmacotherapy-based treatment can be more effective
when accompanied by individual or group-based behav-
ioural therapy programmes conducted by specialised
counsellors.66 The most important factor for successful
smoking cessation still lies on patients’ willingness to quit
smoking. Local smoking cessation services are provided
by, among others, the Department of Health and Hospital
Authority in Hong Kong (Box 2).
Conclusion
Periodontal diseases, dental implant failure, oral cancers,
and precancerous development are linked closely with the
tobacco use. Advising patients to quit tobacco use is a dental
professional responsibility, and the dentists may take an
active role in nicotine replacement counselling. Smoking
cessation should be incorporated as an integral teaching
component of the undergraduate dental curriculum,
particularly with respect to the prevention and diagnosis of
tobacco-induced oral lesions and complications. Close
collaboration of both dentists and physicians with smoking
cessation programmes is advocated in the treatment of
tobacco-smoking patients.
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